#1 Clinical Trials Search in Europe

Fampridine

This article examines the use of Fampridine, also known as dalfampridine or Ampyra, in clinical trials for treating multiple sclerosis (MS). Fampridine is a potassium channel blocker that has shown promise in improving walking ability and other symptoms in MS patients. We’ll explore various studies investigating Fampridine’s effects on mobility, cognition, fatigue, and quality of life in people with MS.

Table of Contents

What is Fampridine?

Fampridine, also known by various other names such as dalfampridine, Ampyra, Fampyra, or BIIB041, is a medication primarily used to improve walking ability in adults with multiple sclerosis (MS). It is a type of drug called a potassium channel blocker, which means it affects how certain electrical signals work in the nervous system[1].

This medication is available as a sustained-release or prolonged-release tablet, which means it releases the active ingredient slowly over time in the body. Fampridine is typically prescribed for patients with MS who have walking disabilities, usually those with an Expanded Disability Status Scale (EDSS) score between 4 and 7[2].

How Fampridine Works

Fampridine works by blocking potassium channels in the nervous system. In MS, the protective covering of nerve fibers (called myelin) is damaged, which can interfere with the transmission of nerve signals. By blocking these potassium channels, fampridine can help improve the conduction of nerve impulses in damaged nerve fibers[3].

Specifically, fampridine:

  • Reduces the leakage of ionic current through potassium channels
  • Prolongs repolarization (the recovery phase of a nerve impulse)
  • Enhances action-potential formation in demyelinated axons (nerve fibers)

By enhancing nerve signal transmission, fampridine may improve various neurological functions, particularly walking ability in people with MS[3].

Conditions Treated by Fampridine

Fampridine is primarily used to treat walking impairments in people with multiple sclerosis. MS is a chronic neurological disorder that affects the central nervous system (brain and spinal cord). It typically affects young and middle-aged adults, with women being more commonly affected than men[3].

In MS, the immune system mistakenly attacks the myelin sheath that protects nerve fibers, leading to various symptoms including:

  • Difficulty walking
  • Fatigue
  • Cognitive impairments (problems with thinking and memory)
  • Visual disturbances
  • Pain
  • Urinary dysfunction

Among these symptoms, walking impairment is one of the most common and disabling. Studies have shown that approximately 75% of individuals with MS experience clinically significant walking disturbances[3].

Benefits of Fampridine

The primary benefit of fampridine is the improvement of walking ability in people with MS. This can be measured in several ways:

  • Increased walking speed
  • Improved performance on timed walking tests
  • Greater walking distance
  • Enhanced balance and coordination

In addition to walking improvements, some studies suggest that fampridine may also have positive effects on:

  • Muscle strength
  • Cognition (thinking and memory)
  • Vision
  • Fatigue
  • Spasticity (muscle stiffness and involuntary muscle spasms)

These potential benefits are still being researched to fully understand the extent of fampridine’s effects[3].

How Fampridine is Administered

Fampridine is typically administered as follows:

  • Oral tablet form
  • Usually 10 mg twice daily
  • Doses should be taken approximately 12 hours apart

It’s important to note that the effectiveness of fampridine can vary among individuals. Generally, doctors will prescribe a trial period of about 2-4 weeks to assess if the medication is beneficial for a particular patient[1][3].

Effectiveness of Fampridine

Studies have shown that fampridine is effective in improving walking ability in about 35-43% of MS patients who try it. These individuals, often referred to as “responders,” typically show a measurable improvement in walking speed (usually defined as at least a 25% increase from baseline)[3].

The effectiveness of fampridine is usually assessed using various walking tests and patient-reported outcomes. Some common measures include:

  • Timed 25-Foot Walk (T25FW): A test measuring how quickly a person can walk 25 feet
  • Six-Minute Walk Test (6MWT): A test measuring how far a person can walk in 6 minutes
  • Multiple Sclerosis Walking Scale (MSWS-12): A questionnaire assessing a patient’s perception of their walking ability

Potential Side Effects

Like all medications, fampridine can cause side effects. Some potential side effects include:

  • Urinary tract infections
  • Insomnia (difficulty sleeping)
  • Dizziness
  • Headache
  • Nausea
  • Balance disorders
  • Back pain

In rare cases, fampridine may increase the risk of seizures. Therefore, it’s typically not prescribed for patients with a history of seizures[4].

Ongoing Research

Research on fampridine is ongoing to better understand its effects and potential benefits. Some areas of current research include:

  • Long-term effects on walking ability and overall quality of life
  • Potential benefits on upper limb function
  • Effects on cognitive function
  • Impact on fatigue and depression in MS patients
  • Use of advanced techniques like ultrasound to measure muscle function in patients taking fampridine

These studies aim to provide a more comprehensive understanding of how fampridine affects various aspects of MS and to potentially expand its use in treating different symptoms of the disease[2][5].

Aspect Details
Primary Uses Improving walking ability in MS patients with EDSS 4-7
Dosage 10 mg twice daily, taken orally
Main Outcomes Measured Walking speed (T25FW), walking ability (MSWS-12), balance (TUG, BBS), quality of life (MSIS-29, MusiQoL)
Other Potential Benefits Improved cognition, reduced fatigue, enhanced upper limb function, better visual function in optic neuritis
Response Rate Approximately 35-40% of patients show significant improvement
Safety Considerations Risk of seizures, urinary tract infections, dizziness; pregnancy registry established
Long-term Studies Ongoing research on effects over 6-12 months and beyond

FAQ

  • What is Fampridine and how does it work? Fampridine is a potassium channel blocker that helps improve nerve conduction in damaged nerves. In multiple sclerosis, it may enhance signal transmission in demyelinated nerve fibers, potentially improving functions like walking ability.
  • What are the main benefits of Fampridine observed in clinical trials? Clinical trials have shown that Fampridine can improve walking speed and distance in some MS patients. It may also have positive effects on balance, upper limb function, fatigue, and quality of life in certain individuals.
  • How is Fampridine typically administered in clinical trials? In most trials, Fampridine is given as a 10 mg oral tablet taken twice daily, with doses spaced about 12 hours apart. Treatment duration in studies ranges from a few weeks to over a year.
  • What percentage of patients typically respond to Fampridine treatment? Studies indicate that about 35-40% of MS patients with walking difficulties may be considered 'responders' to Fampridine, showing significant improvements in walking speed or other mobility measures.
  • Are there any safety concerns with Fampridine use? While generally well-tolerated, some potential side effects include urinary tract infections, insomnia, dizziness, and headache. There is also a small risk of seizures, especially at higher doses. Close monitoring is important during treatment.

Ongoing Clinical Trials on Fampridine

  • Study of fampridine treatment for patients with spinocerebellar ataxia SCA27B caused by FGF14 gene mutation

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Clemastine and Fampridine for Patients with Multiple Sclerosis and Internuclear Ophthalmoparesis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Fampridine: A potassium channel blocker medication used to improve walking in people with multiple sclerosis. Also known as dalfampridine or by brand names like Ampyra or Fampyra.
  • Multiple Sclerosis (MS): A chronic neurological disorder affecting the central nervous system, characterized by damage to the myelin sheath that covers nerve fibers.
  • EDSS (Expanded Disability Status Scale): A method of quantifying disability in multiple sclerosis, ranging from 0 to 10 in 0.5 unit increments.
  • Timed 25-Foot Walk (T25FW): A quantitative measure of lower extremity function, mobility and leg strength in MS patients, involving timing how long it takes to walk 25 feet.
  • MSWS-12 (Multiple Sclerosis Walking Scale): A 12-item self-report measure of the impact of MS on walking ability from the patient's perspective.
  • MSIS-29 (Multiple Sclerosis Impact Scale): A 29-item patient-reported outcome measure assessing the physical and psychological impact of MS.
  • Timed Up and Go (TUG) test: A simple test used to assess a person's mobility and risk of falling, measuring the time taken to stand up from a chair, walk 3 meters, turn, walk back, and sit down.
  • Berg Balance Scale (BBS): A 14-item scale designed to measure balance in a clinical setting, with tasks rated from 0-4 points.
  • ABILHAND: A questionnaire that measures a person's perceived difficulty in performing everyday manual activities.
  • Optic Neuritis (ON): Inflammation of the optic nerve that can cause sudden vision loss, often associated with multiple sclerosis.

References

  1. https://clinicaltrials.gov/study/NCT01480076
  2. https://clinicaltrials.gov/study/NCT03164018
  3. https://clinicaltrials.gov/study/NCT02849782
  4. https://clinicaltrials.gov/study/NCT01480063
  5. https://clinicaltrials.gov/study/NCT03847545